Published in Curr Opin Lipidol on December 01, 2011
Hepatic Inflammation and Physical Performance in Patients With NASH (HELP) | NCT02526732
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig (2013) 1.55
A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med (2014) 1.28
Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology (2014) 1.19
Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol (2013) 1.00
Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat. J Clin Endocrinol Metab (2015) 0.96
Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. Curr Opin Endocrinol Diabetes Obes (2014) 0.96
Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des (2013) 0.95
Childhood obesity: a life-long health risk. Acta Pharmacol Sin (2012) 0.93
Black rice (Oryza sativa L.) extract attenuates hepatic steatosis in C57BL/6 J mice fed a high-fat diet via fatty acid oxidation. Nutr Metab (Lond) (2012) 0.92
Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol (2014) 0.90
Role of Pin1 protein in the pathogenesis of nonalcoholic steatohepatitis in a rodent model. J Biol Chem (2012) 0.85
Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. Int J Endocrinol (2013) 0.84
Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer (2015) 0.80
Weight loss is still an essential intervention in obesity and its complications: a review. J Obes (2012) 0.80
Obesity, but not ethanol, promotes tumor incidence and progression in a mouse model of hepatocellular carcinoma in vivo. Surg Endosc (2013) 0.78
SphK1 mediates hepatic inflammation in a mouse model of NASH induced by high saturated fat feeding and initiates proinflammatory signaling in hepatocytes. J Lipid Res (2015) 0.76
Sonographic assessment of fatty liver: intraobserver and interobserver variability. Int J Clin Exp Med (2014) 0.76
Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. PLoS One (2017) 0.75
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Herbal hepatotoxicity. J Hepatol (2005) 3.98
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest (2008) 2.89
Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med (2012) 2.58
Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology (2009) 2.16
Update on serologic testing in celiac disease. Am J Gastroenterol (2010) 2.07
The incidence and clinical spectrum of refractory celiac disease in a north american referral center. Am J Gastroenterol (2011) 1.96
Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology (2011) 1.85
Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol (2007) 1.82
The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol (2009) 1.77
Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. Nutrients (2013) 1.74
Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol (2013) 1.73
Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology (2008) 1.69
Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol (2003) 1.64
Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol (2005) 1.62
Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice. Hepatology (2011) 1.61
Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology (2013) 1.59
[Prevalence of circulating autoantibodies in healthy individuals]. Med Klin (Munich) (2002) 1.52
Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: the KORA/MONICA Augsburg cohort study 1989-1998. Eur J Epidemiol (2006) 1.51
Pathomechanisms in celiac disease. Int Arch Allergy Immunol (2003) 1.51
Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. Turk J Gastroenterol (2011) 1.48
Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol (2008) 1.47
Endoscopic ultrasound-guided endoscopic necrosectomy of the pancreas: is irrigation necessary? Surg Endosc (2011) 1.46
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol (2003) 1.45
EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc (2006) 1.45
Celiac crisis is a rare but serious complication of celiac disease in adults. Clin Gastroenterol Hepatol (2010) 1.40
Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem (2006) 1.40
Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology (2009) 1.39
Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol (2006) 1.38
Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut (2012) 1.37
Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res (2002) 1.36
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol (2005) 1.35
Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. J Gastroenterol Hepatol (2010) 1.33
Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res (2003) 1.33
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol (2008) 1.31
World Gastroenterology Organisation global guidelines on celiac disease. J Clin Gastroenterol (2013) 1.29
Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol (2004) 1.28
Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion (2004) 1.26
The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol (2002) 1.25
A simple validated gluten-free diet adherence survey for adults with celiac disease. Clin Gastroenterol Hepatol (2009) 1.24
HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem (2010) 1.24
Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology (2005) 1.24
Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol (2006) 1.21
Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology (2010) 1.20
Pathomechanisms in celiac disease. Best Pract Res Clin Gastroenterol (2005) 1.18
Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol (2012) 1.18
Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol (2010) 1.17
Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology (2006) 1.14
Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol (2003) 1.14
Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol (2005) 1.13
Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology (2004) 1.12
Factors that influence adherence to a gluten-free diet in adults with celiac disease. Dig Dis Sci (2008) 1.12
Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat. Hepatology (2005) 1.12
Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat Biotechnol (2012) 1.10
The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol (2006) 1.09
Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med (2005) 1.07
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology (2012) 1.06
Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol (2006) 1.04
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol (2007) 1.04
Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol (2007) 1.03
Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol (2006) 1.03
Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice. Gastroenterology (2007) 1.00
Discovery of a novel and rich source of gluten-degrading microbial enzymes in the oral cavity. PLoS One (2010) 1.00
Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int J Cancer (2006) 0.99
A validated disease-specific symptom index for adults with celiac disease. Clin Gastroenterol Hepatol (2009) 0.99
Matrix metalloproteinase pattern in celiac duodenal mucosa. Lab Invest (2005) 0.97
Identification of Rothia bacteria as gluten-degrading natural colonizers of the upper gastro-intestinal tract. PLoS One (2011) 0.96
Reciprocal modulation of matrix metalloproteinase-13 and type I collagen genes in rat hepatic stellate cells. Am J Pathol (2003) 0.96
Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer (2006) 0.96
Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One (2010) 0.96
Hepatotoxicity of alcohol-induced polar retinol metabolites involves apoptosis via loss of mitochondrial membrane potential. FASEB J (2005) 0.94
Precision-cut liver slices: a tool to model the liver ex vivo. J Hepatol (2013) 0.94
Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol (2003) 0.93
Hypoxia-inducible factor 1 alpha under rapid enzymatic hypoxia: cells sense decrements of oxygen but not hypoxia per se. Free Radic Biol Med (2008) 0.93
Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res (2006) 0.92
In vitro differentiation of human monocytes into dendritic cells by peptic-tryptic digest of gliadin is independent of genetic predisposition and the presence of celiac disease. J Clin Immunol (2008) 0.91
Human intestinal fibroblasts prevent apoptosis in human intestinal mast cells by a mechanism independent of stem cell factor, IL-3, IL-4, and nerve growth factor. J Immunol (2004) 0.91
Epithelial-to-mesenchymal transition in liver fibrosis: dead or alive? Gastroenterology (2010) 0.90
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol (2005) 0.90
VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Biochem Biophys Res Commun (2005) 0.90
Matrix metalloproteinases in necrotising enterocolitis. Pediatr Res (2003) 0.90
Human risk allele HLA-DRB1*0405 predisposes class II transgenic Ab0 NOD mice to autoimmune pancreatitis. Gastroenterology (2010) 0.89
Targeted therapy of liver fibrosis/cirrhosis and its complications. J Hepatol (2011) 0.89
Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B. Hepatology (2004) 0.89
Interstitial collagens I, III, and VI sequester and modulate the multifunctional cytokine oncostatin M. J Biol Chem (2001) 0.88
Role of the receptor for advanced glycation end products in hepatic fibrosis. World J Gastroenterol (2009) 0.88
Liver-homing of purified glucose oxidase: a novel in vivo model of physiological hepatic oxidative stress (H2O2). J Hepatol (2006) 0.88
Nondietary therapies for celiac disease. Gastrointest Endosc Clin N Am (2012) 0.87
Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B. Eur J Gastroenterol Hepatol (2005) 0.87
Monitoring nonresponsive patients who have celiac disease. Gastrointest Endosc Clin N Am (2006) 0.87
Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre. Liver (2002) 0.87
Enhancement of the immune response to residual intrahepatic tumor tissue by laser-induced thermotherapy (LITT) compared to hepatic resection. Lasers Surg Med (2004) 0.86
The role of the immune response against tissue transglutaminase in the pathogenesis of coeliac disease. Autoimmun Rev (2004) 0.86
Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology (2005) 0.86
Regulatory effects of stem cell factor and interleukin-4 on adhesion of human mast cells to extracellular matrix proteins. Blood (2002) 0.86
Microparticles: Modulators and biomarkers of liver disease. J Hepatol (2012) 0.86
Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Am J Physiol Gastrointest Liver Physiol (2012) 0.85